Biogen: earnings after portfolio acquisitions
Biogen’s October reported non-GAAP EPS guidance is $12.20–$13.00. Its higher underlying guidance before specified acquisition and development effects is a separate measure.
Biogen / BIIBPublic biotechEarningsDate to watch
What matters
Watch product sales, guidance and cash needs alongside the headline result. Company filings and the earnings release provide the primary evidence.
Primary evidence
Reporting date unconfirmed — research candidate
Biogen Q3 2026 results and guidancePublished 2026-10-28
Potential outcome market
Will Biogen 2026 reported non-GAAP diluted EPS exceed $12.60?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.